View Older Stories View More Recent Stories

May 15, 2026 06:13AM Insmed (INSM) PT Lowered to $162 at Evercore ISI

May 13, 2026 01:06PM Insmed (INSM) PT Lowered to $185 at Truist Securities

May 12, 2026 12:02PM BofA Securities Reiterates Buy Rating on Insmed (INSM); 'pullback overdone'

May 8, 2026 11:00AM Buy the dip in this stock after a 23% earnings drop: Wall Street

May 7, 2026 07:39AM Insmed (INSM) Tops Q1 EPS by 20c

Apr 16, 2026 07:44AM Insmed (INSM) PT Raised to $230 at Guggenheim

Apr 14, 2026 06:33AM Insmed (INSM) PT Raised to $216 at RBC Capital

Apr 9, 2026 04:27PM Raymond James Starts Insmed (INSM) at Outperform, 'Brinsupri Launch at Peak Performance, With Room to Breathe'

Apr 8, 2026 09:22AM Insmed (INSM) PT Lowered to $212 at BofA Securities

Apr 8, 2026 07:13AM Insmed (INSM) Reiterated at Buy by Stifel Amid Returning Focus on Brinsupri Sales

Apr 8, 2026 07:13AM Insmed (INSM) PT Lowered to $220 at H.C. Wainwright

Apr 8, 2026 06:39AM Insmed (INSM) PT Lowered to $202 at Mizuho

Apr 7, 2026 04:55PM Truist Securities on Insmed (INSM): brensocatib in HS failure unsuprising, 'stock doesn't reflect any meaningful value for HS'

Apr 7, 2026 04:36PM After-hours movers: Levi, Greenbrier, Aehr Test and more

Apr 7, 2026 04:00PM Insmed (INSM) halted, news pending

Mar 30, 2026 08:47AM Stifel on Insmed (INSM): UTHR trial meeting endpoint removes overhang for INSM

Mar 30, 2026 08:43AM Leerink Partners on Insmed (INSM): competitor data gives positive readthrough, continues re-rate

Mar 30, 2026 08:29AM Jefferies on Insmed (INSM): UTHR data 'validates inhaled prostacyclin class in IPF,' INSM's TPIP potl BIC

Mar 30, 2026 04:13AM Morgan Stanley Upgrades Insmed (INSM) to Overweight

Mar 26, 2026 11:16AM Insmed (INSM) PT Raised to $245 at H.C. Wainwright

Mar 24, 2026 08:27AM Insmed (INSM) PT Raised to $206 at Mizuho following positive data

Mar 24, 2026 06:56AM Insmed (INSM) PT Raised to $208 at Stifel: Arikayce Peak Sales Revised Upwards

Mar 23, 2026 12:48PM Insmed (INSM) PT Raised to $213 at BofA Securities

Mar 23, 2026 12:07PM Insmed (INSM) PT Raised to $215 at Leerink Partners

Mar 23, 2026 12:07PM Insmed (INSM) PT Raised to $203 at RBC Capital

Mar 23, 2026 10:13AM Insmed (INSM) PT Raised to $230 at Jefferies

Mar 23, 2026 09:47AM Wolfe Research on Insmed (INSM): 'expect stock to converge toward PT over next few quarters'

Mar 23, 2026 08:48AM William Blair on Insmed (INSM): 'data overall supports approval'

Mar 23, 2026 08:06AM Stifel on Insmed (INSM): Topline data disclosure removes potential NT downside risk

Mar 23, 2026 07:01AM Insmed reports successful phase 3b trial for lung disease drug ARIKAYCE

Mar 22, 2026 10:00AM Jefferies says these are the best SMID-cap biotech stocks to buy

Feb 26, 2026 04:00PM Buy this pharma stock at current levels, Mizuho

Feb 23, 2026 06:37AM H.C. Wainwright Reiterates Buy Rating on Insmed (INSM)

Feb 19, 2026 01:50PM Insmed (INSM) PT Lowered to $205 at Stifel

Feb 19, 2026 07:03AM Insmed (INSM) Misses Q4 EPS by 37c

Jan 23, 2026 05:24AM Roth/MKM Starts Insmed (INSM) at Buy

Jan 21, 2026 09:05AM Insmed (INSM) PT Raised to $200 at RBC Capital

Jan 12, 2026 09:33AM Truist on Insmed (INSM): Brinsupri Launch Outpacing Most Bullish Expectations

Jan 9, 2026 07:02AM Insmed reports strong BRINSUPRI launch with $172.7 million in revenue

Jan 8, 2026 08:49AM 4Q25/2026 Biotech Earnings Preview: RBC

Jan 6, 2026 04:34AM Leerink Partners Reiterates Top Pick on Insmed (INSM)

Dec 19, 2025 06:54AM Goldman Sachs Reiterates Buy Rating on Insmed (INSM)

Dec 19, 2025 02:24AM Truist Securities Assumes Insmed (INSM) at Buy

Dec 18, 2025 10:19AM Insmed (INSM) PT lowered to $230 at H.C. Wainwright

Dec 18, 2025 08:08AM Insmed (INSM) PT Lowered to $241 at TD Cowen as 'Ph2 Brenso BiRCh Misses'

Dec 18, 2025 07:30AM Insmed (INSM) PT Lowered to $212 at Mizuho, 'We're Buyers on Weakness'

Dec 18, 2025 07:11AM Insmed's (INSM) Brensocatib Trial a Disappointment - Stifel

Dec 18, 2025 06:58AM Insmed's (INSM) Brenso Negative Phase 2 Readout A Setback - Cantor Fitzgerald

Dec 18, 2025 06:25AM Insmed (INSM) PT Lowered to $203 at BofA Securities

Dec 18, 2025 04:19AM Insmed (INSM) PT Lowered to $195 at RBC Capital

View More Recent Stories View Older Stories